Puma Raises NERLYNX 2026 Sales View to $205M-$209M, but Q3 Will Test If Q2 Profitability Was Real

Puma's guidance raise improves the story, but Q3 has to confirm it

Puma's update is encouraging, but the stock now needs a second confirmation.

Why the market already rewarded the company

Management is now looking for $205 million to $209 million in full-year NERLYNX net product revenue, after Q2 delivered $0.16 per basic and diluted share in GAAP profit. That combination matters because Puma returned to profitability after a loss in Q1 2026, while NERLYNX demand continued to improve. The stock's move near its 52-week high reflected that progress.

Why Q3 matters more than the raise itself

Once a company shows both better product demand and a return to profit, investors usually look for follow-through. The key question now is whether Q3 repeats Q2's combination of sales strength and profitability, or whether the second-quarter turnaround was only the first step.

Where bulls and bears disagree

Bulls see a simple story: a debt-free company with one commercial product and improving demand. Bears will argue that one strong quarter does not yet establish a durable trend. That is why the next report matters so much.

NERLYNX sales are the clearest test of the business

The main question is not accounting. It is whether NERLYNX is selling better in the market.

Product revenue, net is all NERLYNX

This is a straightforward business to evaluate because product revenue, net consists entirely of revenue from sales of NERLYNX. In Q2, product revenue, net was $53.6 million, up from $49.2 million a year earlier. That suggests prescribing and patient continuation held up rather well.

Management also said there was continued increase in year-over-year demand for NERLYNX, and that demand rose for a second straight year-over-year quarter in the U.S. That is meaningful because it points to commercial momentum rather than a one-off quarter.

What the new full-year target implies

Puma's new full-year range of $205 million to $209 million implies roughly $109.5 million to $113.5 million still needs to come from the second half, after $95.5 million in the first six months. That does not require a dramatic acceleration. It mainly requires NERLYNX to stay close to the Q2 run rate.

If sales hold near that level, the guidance raise looks demand-driven. If demand softens, the first-half improvement may have been more of a restart than a new floor.

Profitability is the harder part of the story

Sales momentum looks credible. Profitability still has to be proven consistently.

What investors need to see next

Puma moved from a loss in Q1 2026 to $8.2 million of Q2 GAAP net income, or $0.16 per basic and diluted share. That is a meaningful turn. But one profitable quarter is a result; two in a row is a pattern.

The company also ended the quarter debt-free after making its final principal payment to Athyrium, so there is no financing change masking the operating story. If Q3 again shows sales strength with controlled expenses, the turn becomes easier to believe.

The bull case: operating leverage could reappear

The bull case is straightforward. NERLYNX is the entire commercial base, and fixed costs do not have to rise much for each additional dollar of product revenue to flow through. In Q2, revenue grew while operating expenses remained relatively controlled. If that pattern continues, the raised outlook will look reasonable rather than aggressive.

The bear case: Q1 may have set a low bar for expenses

Bears have one credible argument: Q1 may have been helped more by cost control than by a full picture of demand. That quarter featured EPS of -$0.07 versus an estimate of about -$0.13, and the narrower loss was widely linked to cost management and operational efficiency.

That is why Q3 is the real test. If expenses rise again or sales cool, Q2 may have been a favorable convergence of demand and discipline rather than the start of a clean turnaround.

What to watch in the next report

Near-term, this is a confirmation trade, not an inspiration trade. The stock is already trading near its 52-week high after the company returned to profit and raised its full-year view on increased demand for NERLYNX.

Positioning checklist

• Watch for follow-through: another solid NERLYNX sales quarter plus sustained GAAP profitability.
• Treat pullbacks more favorably than breakout chases after a sentiment-driven move.
• Check whether the guidance raise still fits the latest demand data instead of getting ahead of it.
• Be cautious if cost control looks more important than durable sales momentum, especially after cost management and operational efficiency helped the Q1 beat.

The core read is simple: the business looks better than it did six months ago, but the next quarter has to prove that the improvement is durable.